Loading...
Please wait, while we are loading the content...
Loperamide, an FDA-Approved Antidiarrhea Drug, Effectively Reverses the Resistance of Multidrug Resistant MCF-7/MDR1 Human Breast Cancer Cells to Doxorubicin-Induced Cytotoxicity
| Content Provider | Scilit |
|---|---|
| Author | Zhou, Yanfei Sridhar, Rajagopalan Shan, Liang Sha, Wei Gu, Xinbin Sukumar, Saraswati |
| Copyright Year | 2012 |
| Description | Loperamide is an FDA-approved antidiarrhea drug which acts on the μ-opioid receptors in the mesenteric plexus of large intestine and exhibits limited side effects. We hypothesized that loperamide might reverse the multidrug resistance (MDR) of human cancer cells to chemotherapeutic agents. MCF-7/MDR1 cells express high level of MDR1 and are resistant to doxorubicin. We found that loperamide significantly enhanced the cytotoxicity of doxorubicin to MCF-7/MDR1 cells in a dose-dependent manner. In conclusion, loperamide reversed the resistance of MCF-7/MDR1 cells to doxorubicin, suggesting that chemotherapy in combination with loperamide may benefit patients with MDR tumors once applied in clinic. |
| Related Links | http://europepmc.org/articles/pmc3305793?pdf=render https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305793/pdf https://www.tandfonline.com/doi/pdf/10.3109/07357907.2011.640653 |
| Ending Page | 125 |
| Page Count | 7 |
| Starting Page | 119 |
| ISSN | 07357907 |
| e-ISSN | 15324192 |
| DOI | 10.3109/07357907.2011.640653 |
| Journal | Cancer Investigation |
| Issue Number | 2 |
| Volume Number | 30 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2012-02-02 |
| Access Restriction | Open |
| Subject Keyword | Journal: Cancer Investigation Oncology Multidrug Resistance Breast Cancer Loperamide Doxorubicin |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Oncology |